


Abrus cantoniensis


Herba Abri (Jigucao), is the dried whole plant of *Abrus cantoniensis* Hance (Fabaceae). It is used for the treatment of jaundice, acute and chronic hepatitis, and mastitis.



Abrus cantoniensis Hance

from oleanane as the active component. The saponinins were identified as cantoniensistriol, sophoradiol, soyasapogenols A and B [1, 2], abrisapogenols A–G [3, 4], and L [5]. These saponinins differ mainly in the number and position of the hydroxy groups.

The major saponins were identified as soyasaponin I and kaikasaponin III [6]. Soyasaponin I is the β -fabatrioside of soyasapogenol B, while kaikasaponin III is the β -fabatrioside of sophoradiol.




Soyasaponin I: R = CH₂OH

Kaikasaponin III: R = CH₃

Chemistry


The whole plant of *A. cantoniensis* is known to contain a series of triterpene saponins with closely related sapogenins derived

Minor saponins are: abrisaponins A, L, D₁ and Ca, representing β -fabatriosides of different sapogenins [5]; and abrisaponins So1, D2, F, and SB, representing β -abritetraosides of different sapogenins [7].




Sophoradiol: R = H

Cantoniensistriol: R = OH



Abrisapogenol A: R = H

Abrisapogenol C: R = OH




Abrisapogenol E: R = H

Abrisapogenol L: R = OH

β -Fabatriose is a triose with a glucuronic acid unit and is structurally 3-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)- β -D-galactopyranosyl-(1 \rightarrow 2)- β -D-glucuronopyranose [5], while β -abritetraose is β -fabatriose with an additional branched glucose.

In addition to triterpene saponins, the hydroxyanthraquinones chrysophanol and physcion were also isolated from *A. cantoniensis* [8]. The anthraquinones are major components of a number of Chinese medicinal materials, such as *Polygonum cuspidatum*, *Polygonum multiflorum*, *Rheum* species (Polygonaceae), and *Rubia cordifolia* (Rubiaceae).



Chrysophanol: R = H

Physcion: R = H₃CO

Pharmacology and Toxicology

The whole plant of *A. cantoniensis* was reported to be used mainly for the treatment of hepatitis and other liver diseases. The major saponins, soyasaponin I and kaikasaponin III, were found to exhibit hepatoprotective activity and to inhibit the elevation of glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) levels in rat liver cells exposed to carbon tetrachloride (CCl₄) [9]. Kaikasaponin III was more effective than soyasaponin I, showing hepatoprotective activity at concentrations less than 100 μ g ml⁻¹. Both, soyasaponin I and kaikasaponin III showed some toxicity at a concentration of 500 μ g ml⁻¹ [7]. Kaikasaponin III and soyasaponin I also exerted protective effects in primary cultured rat hepatocytes

against damage induced by hepatocyte antiserum. Sophoradiol also showed some protective activity, but was less potent than kaikasaponin III [10]. In a study using HepG₂ cells, sophoradiol exhibited potent protective activity against the toxicity of *tert*-butyl hydroperoxide [11].

Soyasaponin I was found to be a potent and specific sialyltransferase inhibitor, inhibiting cellular α 2,3-sialyltransferase activity. Soyasaponin I was found only to inhibit sialyltransferase, but not other glycosyltransferases and glycosidases tested [12]. Tumor formation and invasive behavior is believed to be associated with altered sialyltransferase activity. Soyasaponin I did not affect the cell cycle, and also failed to inhibit the cell proliferation of nonmetastatic MCF-7 and highly metastatic MDA-MB-231 human mammary carcinoma cells. It was, however, confirmed to inhibit cellular α 2,3-sialyltransferase activity and to depress expression at the tumor cell surface of α 2,3-sialic acid [13]. Soyasaponin I, as a specific sialyltransferase inhibitor, also inhibited the expression of α 2,3-linked sialic acids in the highly metastatic B16F10 cancer cell surface, decreased the migratory ability of cells, and enhanced cell adhesion to extracellular matrix proteins. In addition, the alteration of glycosylation significantly reduced the ability of tumor cells to disseminate to the lungs of mice in a pulmonary metastasis assay [14].

After a single oral dose of soy extract containing about 430 μ M soyasaponins with sayasapogenol B as aglycone was given to healthy women, neither soyasaponins nor their metabolites were detected in 24 h urine samples. Soyasapogenol B as a major metabolite of group B soyasaponins was found in a 5 day fecal collection at a total content of about 36 μ M; however, no group B soyasaponins were detected in the feces. An *in vitro* study using Caco-2 human colon cancer cells revealed that the mucosal transfers of soyasaponin I, and soyasapogenol B

were only 0.5–2.9% and 0.2–0.8%, respectively, after 4 h incubation. The results showed that soyasaponins were very poorly absorbed in human intestinal cells. Rather, they appeared to be metabolized to soyasapogenol B by human intestinal microorganisms *in vivo* and excreted in the feces. Soyasaponin I did not show cytotoxicity on Caco-2 cells at concentrations up to 3 μ M, whereas soyasapogenol B at 1 μ M significantly reduced cell viability [15].

The ethanol extract of the herb of *Abrus cantoniensis* was reported to be active against *Helicobacter pylori*. It inhibited all five clinically isolated strains of *H. pylori* tested *in vitro*, with a median inhibitory concentration of approximately 40 μ g ml⁻¹ [16]. Kaikasaponin III was reported to exert a potent inhibitory activity against herpes simplex virus type 1 (HSV-1), whereas the inhibitory activity of sophoradiol against HSV-1 was less potent compared to kaikasaponin III [17].

References

- Chiang, T.C. and Chang, H.M. (1982) Isolation and structural elucidation of some sapogenols from *Abrus cantoniensis*. *Planta Med.*, **46**, 52–55.
- Mak, T.C.W., Chiang, T.C., and Chang, H.M. (1982) X-ray crystal structures of cantoniensistriol and sophoradiol: two oleanane-type triterpenes from the roots of *Abrus cantoniensis* Hance. *J. Chem. Soc., Chem. Commun.*, 785–786.
- Sakai, Y., Takeshita, T., Kinjo, J., Ito, Y., and Nohara, T. (1990) Leguminous plants. XVII. Two new triterpenoid sapogenols and a new saponin from *Abrus cantoniensis* 2. *Chem. Pharm. Bull. (Tokyo)*, **38**, 824–826.
- Takeshita, T., Hamada, S., and Nohara, T. (1989) New triterpenoids from *Abrus cantoniensis* 1. *Chem. Pharm. Bull. (Tokyo)*, **37**, 846–848.
- Miyao, H., Sakai, Y., Takeshita, T., Kinjo, J., and Nohara, T. (1996) Triterpene saponins from *Abrus cantoniensis* (Leguminosae). I. Isolation and characterization of four new saponins and a new sapogenol. *Chem. Pharm. Bull. (Tokyo)*, **44**, 1222–1227.
- Miyao, H., Arai, T., Udayama, M., Kinjo, J., and Nohara, T. (1998) Kaikasaponin III and soyasaponin I, major triterpene saponins of *Abrus cantoniensis*, act on GOT and GPT: influence on transaminase elevation of rat liver cells concomitantly exposed to CCl₄ for one hour. *Planta Med.*, **64**, 5–7.
- Miyao, H., Sakai, Y., Takeshita, T., Ito, Y., Kinjo, J., and Nohara, T. (1996) Triterpene saponins from *Abrus cantoniensis* (Leguminosae). II. Characterization of six new saponins having a branched-chain sugar. *Chem. Pharm. Bull. (Tokyo)*, **44**, 1228–1231.
- Wong, S.M., Chiang, T.C., and Chang, H.M. (1982) Hydroxyanthraquinones from *Abrus cantoniensis*. *Planta Med.*, **46**, 191–192.
- Kinjo, J. (1996) Bioactive compounds from leguminous plants – structures, activities, HPLC profiles and functional importance of sugar moiety for oleanane glucuronides. *Nat. Med.*, **50**, 79–85.
- Kinjo, J., Ikeda, T., Okawa, M., Udayama, M., Hirakawa, T., Shii, Y., and Nohara, T. (2000) Hepatoprotective and hepatotoxic activities of sophoradiol analogs on rat primary liver cell cultures. *Biol. Pharm. Bull.*, **23**, 1118–1121.
- Kinjo, J., Hirakawa, T., Tsuchihashi, R., Nagao, T., Okawa, M., Nohara, T., and Okabe, H. (2003) Hepatoprotective constituents in plants. 14. Effects of soyasapogenol B, sophoradiol, and their glucuronides on the cytotoxicity of tert-butyl hydroperoxide to HepG₂ cells. *Biol. Pharm. Bull.*, **26**, 1357–1360.
- Wu, C.Y., Hsu, C.C., Chen, S.T., and Tsai, Y.C. (2001) Soyasaponin I, a potent and specific sialyltransferase inhibitor. *Biochem. Biophys. Res. Commun.*, **284**, 466–469.
- Hsu, C.C., Lin, T.W., Chang, W.W., Wu, C.Y., Lo, W.H., Wang, P.H., and Tsai, Y.C. (2005) Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. *Gynecol. Oncol.*, **96**, 415–422.
- Chang, W.W., Yu, C.Y., Lin, T.W., Wang, P.H., and Tsai, Y.C. (2006) Soyasaponin I decreases the expression of α 2,3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. *Biochem. Biophys. Res. Commun.*, **341**, 614–619.

- 15 Hu, J., Reddy, M.B., Hendrich, S., and Murphy, P.A. (2004) Soyasaponin I and saponigenol B have limited absorption by Caco-2 intestinal cells and limited bioavailability in women. *J. Nutr.*, **134**, 1867–1873.
- 16 Li, Y., Xu, C., Zhang, Q., Liu, J.Y., and Tan, R.X. (2005) *In vitro* anti-*Helicobacter pylori* action of 30 Chinese herbal medicines used to treat ulcer diseases. *J. Ethnopharmacol.*, **26**, 329–333.
- 17 Kinjo, J., Yokomizo, K., Hirakawa, T., Shii, Y., Nohara, T., and Uyeda, M. (2000) Anti-herpes virus activity of fabaceous triterpenoidal saponins. *Biol. Pharm. Bull.*, **23**, 887–889.